Lilly Announces Agreement to Acquire Prevail Therapeutics
Lilly Announces Agreement to Acquire Prevail Therapeutics Dec 24, 2020 12:07 PM ET Legal Newswire POWERED BY LAW.COM Eli Lilly and Company and Prevail Therapeutics Inc. announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR i...
Source: law.com